Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (1611)	6/30/1998 4:17:00 PM
From: Altaf Amin Jadavji	Respond to of 2205

Check this out ... Oouch for ORG shareholders --from briefing.com-- 13:27 ET Organogenesis Inc (ORG) 19 1/8 -1 3/16: Wedbush Morgan initiates coverage of biotech issue with a "sell" rating and a 12-18 month downside price target of $4.25 a share, 78% below the stock's current price. Shorting ORG is certainly not a new idea. Stock has one of the highest short-interest ratios around, approx. 41 days, which is more than triple the S/I ratio of another of the market's most heavily-shorted stocks, Micron Technology (MU).

To: Rick Strange who wrote (1611)	7/1/1998 8:08:00 PM
From: Marshall Teitelbaum	Read Replies (1) \| Respond to of 2205

Rick and all, For those who didn't see, Wedbush(Alex Arrow) recently downgraded ORG, and today ORG responded: http//biz.yahoo.com/bw/980701/organogene_1.html It was all pretty interesting. ORG looks to not be worried about slinging mud and making enemies right now, right or wrong about their product. Some interesting comments ORG made though, such as inferring that dermagraft was turned down rather than given a letter of nonapproval....rejection and delay are two very different words. For those who haven't read Alex Arrow's discussions before about biotech/tissue engineering, he gives very good fundamental descriptions of the industry and the specific companies. Although it is a small company, his reports have been far more fundamentally correct than just about any other analyst I have read over the last year, regardless of current stock price. Predicting actual earnings or dates of fda approvals is trickier. I haven't gotten to read his report about ORG to comment, but I have found his comments about ATIS to be very forthcoming. FWIW, he has acknowledged that Wedbush maintains a market share in ATIS. He downgraded them from accumulate to hold on the day of the nonapproval news, and soon after upgraded them to accumulate again, given the change in the valuation..etc. On one hand, Wedbush could be said to be pushing for a company they own, but on the other hand, why wouldn't they own shares in a company they believe has a very sound fundamental future? Trying to test that 4.5 resistance. Will be interesting to see if it breaks through or settles back a bit, although it looks like you are correct, Rick. I'd be surprised to see the low get back to the 3s again without bad news, or at least below the upper 3s. Take care, Marshall